



## CONTENTS

Preface  
Contributors

iii  
iv

### SECTION I INTRODUCTION

#### 1 INTRODUCTION

##### The Editors

Immunity: Innate and adaptive	1.1
Functions of the adaptive immune system	1.1
Functions of antibodies	1.1
Functions of T cells	1.2
Function of neutrophils, eosinophils & macrophages	1.3
Functions of the complement system	1.3
Introduction to immunopathology	1.4
Hypersensitivity	1.5
Type I	1.5
Type II	1.5
Type III	1.6
Type IV	1.7

### SECTION II TRANSPLANTATION

#### 2 HLA AND DISEASE

##### Dr T Lund & the late Professor H Festenstein

Human leucocyte antigens (HLA)	2.1
HLA molecules	2.1
HLA locus	2.3
DNA typing techniques	2.6
Haplotypes	2.8
HLA and disease	2.8
Statistical considerations	2.8
How HLA molecules influence disease	2.10

#### 3 TRANSPLANTATION

##### Professor J R Batchelor

Kidney transplantation	3.1
Genetic similarity of donor and recipient	3.1
Immunosuppressive regimen	3.3
Immunological status of recipient	3.4
Immune status of recipient after transplantation	3.6
Heart transplantation	3.7
HLA matching before transplantation	3.7
Liver transplantation	3.8
Immunogenicity of liver	3.8
HLA matching before transplantation	3.8
Corneal transplantation	3.9
Expression of HLA molecules	3.9
Rejection	3.9
HLA matching	3.9
Cross matching	3.9
Immunosuppression	3.9
Bone marrow transplantation	3.10
Matching for bone marrow transplantation	3.10
Results of bone marrow transplantation	3.13

### SECTION III RHEUMATOLOGICAL DISORDERS

#### 4 PRINCIPLES OF AUTOIMMUNITY

##### Professor I M Roitt

Self tolerance	4.1
The concept of autoimmune disease	4.2
The spectrum of autoimmune disease	4.3
Aetiology	4.4
Autoimmune diseases are multifactorial	4.6
Evidence that autoimmunity can cause disease	4.7
Evidence from experimental autoimmunity	4.7
Evidence from human disease	4.9
Diagnostic and prognostic aspects	4.10

#### 5 RHEUMATOID ARTHRITIS & OTHER JOINT DISEASES

##### Dr P Venables

Rheumatoid arthritis	5.1
Clinical and pathological features	5.1
Aetiology of RA	5.3
Pathology and immunohistopathology of the joint	5.6
Immunopathology of cells in the blood	5.9
Autoantibodies and immune complexes in RA	5.10
Diagnosis of rheumatoid arthritis	5.11
Drug treatment	5.12
Juvenile chronic arthritis	5.12
Juvenile RA	5.12
Pauciarticular and polyarticular JCA	5.12
Systemic JCA	5.12
Seronegative spondyloarthropathies	5.13
Ankylosing spondylitis	5.13
Reactive arthritis	5.14
Arthritis and inflammatory bowel disease	5.15
Psoriatic arthritis	5.15

#### 6 SLE & OTHER CONNECTIVE TISSUE DISORDERS

##### Dr M Snaith

Systemic lupus erythematosus	6.1
Clinical features	6.1
Immunological responses	6.4
Therapy	6.8
Monitoring	6.8
Prognosis	6.8
Scleroderma	6.9
Clinical features	6.9
Pathological features	6.10
Immunological responses	6.10
Analogues of scleroderma	6.10
Immunogenetics	6.11
Diagnosis of scleroderma	6.11
Prognosis	6.12
Treatment	6.12
Sjögren's syndrome	6.12
Definitions	6.12
Primary Sjögren's syndrome	6.12
Immunological responses	6.13
Pathology	6.13
Variants	6.14

## SECTION IV ORGAN-BASED DISEASE

### 7 ENDOCRINE DISORDERS

#### Dr R Mirakian

Organ- versus non-organ-specific autoimmune disease	7.1
Spectrum of organ-specific disease	7.1
Polyglandular syndromes	7.2
Mechanisms of organ damage	7.3
Destructive mechanisms	7.3
Stimulating autoantibodies	7.4
Blocking autoantibodies	7.4
Cell-mediated immunity (CMI)	7.5
Organ-based disease	7.6
Thyroid	7.6
Stomach	7.8
Pancreas: Diabetes mellitus	7.8
Adrenal	7.10
Gonad and placenta	7.11
Pituitary	7.12
Parathyroid	7.12
Skin	7.13
HLA and autoimmune disease	7.13
Inappropriate expression of HLA in autoimmunity	7.13

### 8 RENAL DISORDERS

#### Dr P Sweny

Classification of renal disease	8.1
Kidney susceptibility to immune-mediated damage	8.1
Glomerulonephritis	8.2
Animal models	8.2
Mediators of inflammation	8.6
Cell-mediated immunity and GN	8.7
Human GN	8.7
Anti-GBM antibody-mediated GN	8.12
The multisystem vasculitides	8.14
Acute allergic tubulo-interstitial nephritis	8.15
Immune complex-associated tubulo-interstitial nephritis	8.16
Anti-tubular BM antibody-associated tubulo-interstitial nephritis	8.16
Dense deposit disease (type II MCGN)	8.16
Amyloidosis	8.17

### 9 NEUROLOGICAL DISORDERS

#### Dr D Male

Introduction	9.1
Interaction between CNS and immune system	9.1

#### Professor A Compston

Multiple sclerosis	9.2
Immunogenetics	9.4
Aetiology	9.4
Investigation of MS	9.6
Treatment	9.7

#### Dr G K Scadding

Post-infectious neurological disorders	9.7
Treatment	9.8

#### Dr J Winer

Guillain-Barré syndrome (GBS)	9.7
-------------------------------	-----

#### Dr G K Scadding

Reye's syndrome	9.8
Sub-acute and chronic encephalomyelitis	9.9
Sub-acute sclerosing pan-encephalitis (SSPE)	9.9
Chronic encephalitis with unconventional agents	9.9

#### Professor J Newsom-Davis

Autoimmune neurological disorders	9.10
Myasthenia gravis (MG)	9.10
Lambert-Eaton myasthenic syndrome	9.14

### 10 GASTROINTESTINAL & LIVER DISORDERS

#### Dr D P Jewell

Gastrointestinal disorders	10.1
Gastritis	10.2
Coeliac disease	10.4
Other food-sensitive small intestinal enteropathies	10.6
Ulcerative colitis and Crohn's disease	10.6
Liver disorders	10.8
Hepatitis B	10.9
Chronic active hepatitis	10.10
Primary biliary cirrhosis	10.12

### 11 CARDIOVASCULAR DISORDERS

#### Professor W A Littler and Dr P J Lowry

Introduction	11.1
Rheumatic heart disease	11.1
Bacterial endocarditis	11.3
Post-cardiotomy syndrome	11.5
Cardiomyopathy	11.6
Congestive cardiomyopathy	11.6
Hypertrophic cardiomyopathy	11.8
Restrictive cardiomyopathy	11.8
Atherosclerosis	11.9
Immunological diseases	11.10
Connective tissue diseases	11.10
Systemic vasculitis	11.1
Chagas' disease	11.12
Acute phase	11.12
Latent phase	11.13
Chronic phase	11.13
Retroperitoneal fibrosis	11.13

### 12 PULMONARY DISORDERS

#### Dr A Greening

Introduction	12.1
Lung injury	12.1
Emphysema	12.2
Adult respiratory distress syndrome (ARDS)	12.2
Respiratory tract infections	12.3
Infective rhino-sinusitis	12.3
Chronic bronchitis	12.4
Bronchiectasis	12.5
Pneumonia	12.6
Bronchial asthma	12.7
Interstitial fibrosing disorders	12.7
Extrinsic allergic alveolitis	12.9
Allergic bronchopulmonary aspergillosis	12.10
Granulomatous pulmonary disorders	12.12
Immune complex mediated and related disorders	12.14
Pulmonary vasculitis	12.14
Connective tissue disorders	12.15
Pulmonary eosinophilia	12.15
Pathogenesis	12.16

### 13 OPHTHALMIC DISORDERS

#### Professor D L Easty and Dr G Fahy

Introduction	13.1
Protection of the eye	13.1
Physical factors	13.1
Immune features: anterior segment	13.2
Immune features: cornea	13.2

Manifestations of ocular disease	13.3	Gastrointestinal diseases	15.10
Allergic disorders	13.5	Dermatological diseases	15.11
Vernal eye disease	13.5	Connective tissue diseases	15.12
Eye drop allergy	13.6	<i>Candida</i> infections	15.13
Contact lens related allergies	13.6		
Isolated ocular immune disease	13.7	<b>16 IMMUNOHAEMATOLOGY</b>	
Systemic diseases with ocular manifestations	13.8	<b>Professor A H Waters</b>	
Rheumatoid disorders	13.9	Mechanisms of immune destruction of blood cells	16.1
Connective tissue disorders	13.10	Intravascular haemolysis	16.1
Mucocutaneous disorders	13.10	Classification of blood cell antibodies	16.3
Gastrointestinal disorders	13.11	Blood transfusion	16.3
Orbital disorders	13.11	Blood group systems	16.3
Immunodeficiency states	13.12	Demonstration of red cell antibodies	16.5
		Leucocyte and platelet antigens	16.6
		Immunological consequences of blood transfusion	16.7
		Alloimmunization	16.7
		Incompatibility	16.7
		Alloimmune neonatal cytopenias	16.11
		Haemolytic disease of the newborn (HDN)	16.12
		Alloimmune neonatal thrombocytopenia and neutropenia	16.13
		Autoimmune cytopenias	16.13
		Autoimmune haemolytic anaemia (AIHA)	16.13
		Autoimmune thrombocytopenia	16.15
		Autoimmune neutropenia	16.16
		Autoimmune suppression of progenitor cells	16.17
		Aetiology of autoantibody production	16.17
		Drug-induced immune cytopenias	16.17
		Mechanisms of cell destruction	16.17
		<b>SECTION V GENERAL HYPERSENSITIVITY</b>	
<b>14 SKIN DISORDERS</b>		<b>17 ALLERGY</b>	
<b>Professor R StC Barnetson and Dr D Gawkrödger</b>		<b>Dr J Brostoff and Dr G K Scadding</b>	
Introduction	14.1	Type I hypersensitivity	17.1
Diseases caused by type I hypersensitivity	14.1	Atopy	17.1
Urticaria	14.1	Immunoglobulin E	17.1
Other causes of urticaria	14.2	Control of IgE production	17.2
Diseases caused by type II hypersensitivity	14.3	The allergic response in man	17.4
Pemphigus	14.4	Environmental factors	17.4
Pemphigoid	14.4	Non-specific factors	17.4
Diseases caused by type III hypersensitivity	14.5	Specific factors	17.4
Allergic vasculitis (leucocytoclastic vasculitis)	14.6	Genetic mechanisms	17.5
Urticarial vasculitis	14.6	Cells involved in the allergic response	17.6
Erythema nodosum	14.6	Mast cells	17.6
Erythema nodosum leprosum	14.7	Structure and function of Fc receptors for IgE	17.7
Polyarteritis nodosa	14.7	Mast cell triggering	17.8
Erythema multiforme	14.7	Mediator release	17.9
Dermatitis herpetiformis (DH)	14.8	Basophils	17.10
Disease caused by type IV hypersensitivity	14.9	Eosinophils	17.10
Allergic contact dermatitis	14.9	Platelets	17.11
Atopic eczema	14.11	Clinical aspects of allergic disease	17.11
Borderline leprosy reaction	14.12	Asthma	17.12
Immunodeficiency diseases	14.13	Virus infection and asthma	17.13
Lepromatous leprosy (in the tropics)	14.13	Allergic rhinitis	17.14
Diffuse cutaneous leishmaniasis (in Ethiopia and South America)	14.13	Anaphylaxis	17.14
Chronic mucocutaneous candidiasis	14.14	Bee and wasp venom allergy	17.15
Immunodeficiency in atopic eczema	14.14	Food allergy	17.15
Generalized herpes zoster infections	14.15	Treatment of allergic diseases	17.16
Immunodeficiency and papilloma (wart) viruses	14.15		
Acquired immunodeficiency syndrome (AIDS)	14.15		
Connective tissue diseases	14.15		
Lupus erythematosus (LE)	14.15		
Scleroderma	14.15		
Neoplasia	14.16		
Basal cell carcinoma	14.16		
Squamous cell carcinoma	14.16		
Malignant melanoma	14.16		
Skin lymphomas	14.17		
Kaposi's sarcoma	14.17		
<b>15 ORAL DISORDERS</b>		<b>18 OCCUPATIONAL LUNG DISORDERS</b>	
<b>Professor S Challacombe</b>		<b>Dr A J Newman-Taylor</b>	
Introduction	15.1	Introduction	18.1
The secretory immune system	15.1	Definition of asthma	18.2
Stimulation of the secretory immune system	15.2		
Specific oral diseases	15.4		
Dental caries	15.4		
Periodontal diseases	15.5		
Apthous ulcers	15.8		
Behçet's syndrome	15.9		
Oral manifestations of systemic immunological diseases	15.10		

Occupational asthma	18.3
Inhaled agent	18.3
Importance of occupational asthma	18.4
Characteristics of response	18.4
Diagnosis of occupational asthma	18.5
Management of occupational asthma	18.7
Granulomatous inflammation	18.8
Chronic beryllium disease	18.8
Extrinsic allergic alveolitis	18.10

## ✓ 19 DRUG HYPERSENSITIVITY

### Dr C H Dash

Introduction	19.1
Manifestations of drug hypersensitivity	19.1
Organ-based effects	19.2
Dermatological	19.2
Haematological	19.4
Hepatic	19.7
Renal	19.7
Pulmonary	19.8
The immune response to drugs	19.8
Sources of antigens in drugs	19.9
Penicillin as a model for drug hypersensitivity	19.10
Benzylpenicillin	19.10
Minor determinants	19.11
Other penicillins	19.11
Cephalosporins	19.11
Other $\beta$ -lactams	19.12
Factors predisposing to drug hypersensitivity	19.12
Diagnosis of drug hypersensitivity	19.13
Management of drug hypersensitivity	19.13

## SECTION VI NEOPLASIA

## 20 CANCER

### Dr M Moore and Dr SE Christmas.

Clinical relevance of experimental tumours	20.1
Immunity and tumour prevention	20.1
Immune response against established tumours	20.2
Tumour antigenicity	20.3
Escape from immunosurveillance	20.5
✓ Anti-tumour effector mechanisms	20.6
Importance of cellular responses	20.8
Antibody response to tumours	20.9
<i>In vitro</i> tests for tumour immunity	20.9
Cellular responses	20.9
Humoral responses	20.10
Therapeutic approaches	20.11

## 21 LYMPHORETICULAR DISORDERS

### Professor M F Greaves

Introduction	21.1
Phenotypic characterization of leukaemias and lymphomas	21.2
✓ 21.4 Immunophenotypic analysis	21.2
Genotypic alterations in leukaemia and lymphoma	21.8
Involvement of Ig and TCR genes in leukaemogenesis	21.8
The natural history of lymphoid malignancy	21.13
Clinical applications of leukaemia biology	21.17

## SECTION VII IMMUNODEFICIENCY AND INFECTION

## ✓ 22 PRINCIPLES OF IMMUNITY TO INFECTION

### Professor J H L Playfair

Classes of parasitic organisms	22.1
Routes of entry	22.1
Multiplication and spread	22.2 ✓
Pathology	22.3
Natural immunity	22.4 ✓
Adaptive immunity	22.6 ✓
Immunopathology	22.7
Parasite survival mechanisms	22.8
Host-parasite balance and imbalance	22.10 ✓

## 23 CONGENITAL IMMUNODEFICIENCY SYNDROMES

### Professor A R Hayward

Introduction	23.1
Antibody deficiency syndromes	23.1
Congenital agammaglobulinaemia	23.1
X-linked immunodeficiency with IgM	23.3
Variable hypogammaglobulinaemia syndromes	23.3
Other immunoglobulin deficiency syndromes	23.4
Selective IgA deficiency	23.4
Selective deficiencies of IgG subclasses	23.5
Defects of cell-mediated immunity	23.5
Selective defects of T cells	23.5
Purine nucleoside phosphorylase deficiency	23.5
Combined immunodeficiency syndromes	23.6
Adenosine deaminase deficiency	23.6
Other types of SCID	23.7
Treatment of SCID syndromes	23.7
Other primary immunodeficiency syndromes	23.8
Wiskott-Aldrich syndrome	23.8
Ataxia telangiectasia	23.8
Chronic mucocutaneous candidiasis	23.8
Environmental defects	23.8
Thymic hypoplasia (Di George syndrome)	23.8
Phagocyte defects	23.9
LFA-1 or iC3b receptor deficiency	23.9
Chronic granulomatous disease	23.9
Chediak-Higashi syndrome	23.9
Lazy leucocyte syndrome	23.10
Complement defects	23.10

## ✓ 24 AIDS & HIV INFECTION

### Dr A J Pinching

Introduction	24.1
Epidemiology	24.1
Transmission	24.2
Clinical features	24.2
Spectrum of outcome	24.2
AIDS related complex	24.3
AIDS	24.4
Pathogenesis	24.4
Cells infected by HIV	24.4
HIV genes and pathogenicity	24.7
Factors affecting natural history	24.8
Laboratory markers for HIV infection	24.9
HIV antibody	24.9
HIV antigen	24.9
Prognostic markers for progression	24.10
CD4 <sup>+</sup> cell count	24.10
Skin and lymphocyte function tests	24.10
Specific antigens and antibodies	24.10

Immune responses to HIV	24.11
Treatment	24.11
Strategies	24.11

Steroids	27.4
Antibodies as immunosuppressants	27.6
Cyclosporin	27.7

## 25 NUTRITION & IMMUNITY

### Professor RK Chandra

Introduction	25.1
Protein-energy malnutrition (PEM)	25.2
Lymphoid organs	25.3
Cell-mediated immunity	25.3
Antibody responses	25.6
Phagocytic cells	25.7
Complement system	25.7
Immunological effects of fetal malnutrition	25.7
Nutrition and immune competence in old age	25.8
Single nutrient deficiencies and immune function	25.9
Trace elements	25.9
Immunological alterations in overnutrition	25.10
Generalized overnutrition	25.10
Excess intake of single nutrients	25.10
Conclusions	25.10

## SECTION VII IMMUNE INTERVENTION

### 26 VACCINES

#### EXISTING VACCINES - Professor JR Pattison

Introduction	26.1
Vaccine administration	26.1
Systemic versus mucosal infections	26.1
Inactivated versus live-attenuated vaccines	26.3
Types of immunization	26.3
Passive immunization	26.3
Active immunization	26.4
Combined active and passive immunization	26.8

#### FUTURE TRENDS - Dr DJ Rowlands

Introduction	26.9
Live vaccines	26.9
Directed attenuation	26.9
Live vectors	26.9
Non-replicating vaccines	26.11
Expression of immunogenic proteins by genetic engineering	26.11
Synthetic peptide vaccines	26.13
Anti-idiotypic vaccines	25.14
Antigen presentation	26.15

### 27 IMMUNOSUPPRESSION

#### Dr D White

Introduction	27.1
Irradiation	27.1
Pharmacological immunosuppression	27.3
Purine analogues	27.3

### 28 IMMUNOPOTENTIATION

#### Dr A C Allison

Introduction	28.1
Adjuvants	28.1
A new generation of vaccines	28.2
Effects of adjuvants on elicited antibodies	28.4
Elicitation of cell-mediated immunity	28.5
Mode of action of adjuvants	28.6
Immunopotential for human vaccines	28.7
Bacterial vaccines	28.10

### 29 PLASMAPHERESIS

#### Professor TJ Hamblin

History	29.1
Techniques	29.1
Centrifugal techniques	29.1
Filtration techniques	29.3
Selective plasmapheresis	29.4
Replacement fluid	29.5
Effect of plasmapheresis on plasma components	29.5
Effect on immunoglobulin catabolism	29.6
Effect on immunoglobulin synthesis	29.7
Synergy with immunosuppressive drugs	29.8
Effect on inflammatory mediators	29.8
Effect of plasmapheresis on cellular immunity	29.8
Complications	29.8
Clinical applications	29.9
Hyperviscosity syndrome	29.9
Antibody mediated diseases	29.9
Immune complex mediated diseases	29.11

## SECTION IX IMMUNOLOGICAL TESTS

### 30 LABORATORY INVESTIGATIONS

#### Dr R A Thompson

Introduction	30.1
Assessment of antigens	30.1
Assessment of specific antibodies	30.2
Antibodies to extrinsic antigens	30.2
Antibodies to intrinsic antigens (autoantibodies)	30.2
Evaluation of humoral immunodeficiency	30.8
Lymphocyte tests	30.9
Immunoglobulin analysis	30.11
Complement	30.12
Immune complexes	30.14
Polymorph tests	30.15
Macrophage tests	30.15